Immune Checkpoint Inhibitor Induced Inflammatory Arthritis and Sicca Syndrome

screen-shot-2016-09-19-at-9-44-09-pm

Welcome back #RheumJC friends!

After enjoying a little summer break, #RheumJC is happy to announce our next journal club will be Thursday, September 29th.

We’ll be discussing the Annals of the Rheumatic Disease article Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab by Dr. Laura C Cappelli, et al.

We are also extremely pleased to that the author, Dr. Laura Cappelli, will be joining us for the first one-hour session.

Dr. Laura Cappelli (@cappelliMD) is a staff rheumatologist with Johns Hopkins Division of Rheumatology.

BMJ has graciously made Dr. Cappelli’s article and the accompanying editorial free to access from 22nd September to 6th October (until one week after the journal club).

If needed, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Missed opportunities in the 2015 ACR guideline for RA treatment

shutterstock_19456234-600w

Greetings #RheumJC friends!

We’re tremendously excited to announce our next journal club will be Thursday, June 30th, 2016 discussing the Nature Reviews Rheumatology article: Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment by Dr. Ronald van Vollenhoven.

As usual, we will have two one-hour sessions:

Nature Reviews Rheumatology has graciously made Dr. van Vollenhoven’s article free to access from now until July 7, 2016 via the above link.

For reference, here is a link to the 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis by Singh J., et al.

If needed, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

IL-6 Blockade with Tocilizumab for Scleroderma

512px-Fibroblast_(BPAE)
Fibroblast image by Heiti Paves (Own work) [CC BY-SA 3.0], via Wikimedia Commons.

The next session of #RheumJC will be Thursday, June 2, 2016, discussing a recent article from The Lancet by Khanna, D., et al, looking at the role of IL–6 blockage in scleroderma, titled Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

This article is open access and can found on The Lancet or via PubMed.

*** We goofed! This article isn’t actually open access, but we’ll do a rundown of the article on Twitter during the #RheumJC session.***

We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).

If needed, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

Secukinumab (IL-17A blockage) in Psoriatic Arthritis

shutterstock_296497013-600w

Greetings rheumatology friends! The next session of #RheumJC will be Thursday, May 5, 2016, where we will be discussing secukinumab, an anti-interleukin–17A monoclonal antibody that was recently FDA approved for the treatment of psoriatic arthritis. The article we’ll be discussing was published in October 2015 in the New England Journal of Medicine and is titled Secukinumab Inhibition of Interleukin–17A in Patients with Psoriatic Arthritis. We again expect a lively discussion about this new treatment option.

This article is open access and can found at this link: http://www.nejm.org/doi/full/10.1056/NEJMoa1412679

A direct link to the PDF is available here: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412679

We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

The Link Between Periodontal Disease and Rheumatoid Arthritis

teeth-header-600w

Greetings! The next session of #RheumJC will be on Thursday, March 31, 2016, where we will be discussing a recent meta-analysis looking at a potential environmental link between periodontal disease and rheumatoid arthritis titled “Hand to Mouth: A Systematic Review and Meta-Analysis of the Association between Rheumatoid Arthritis and Periodontitis” by Fuggle, NR, et al. This promises to be a lively discussion so we hope you can join.

This article is open access and can found at this link: http://journal.frontiersin.org/article/10.3389/fimmu.2016.00080/full

We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

The Role of Varicella-Zoster Virus (VZV) as a Trigger of Giant Cell Arteritis

artery-stock-600w

Greetings! For our second session of #RheumJC for the year on Thursday, February 25, 2016, we will be discussing a recent article from the journal Neurology which may offer insights into the pathophysiology of giant cell arteritis titled “Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis” by Gilden, D. et al.

We will again have two one-hour sessions at 9pm GMT (4pm EST) and 3am GMT (10pm EST).

We greatly thank the editors of the journal Neurology, who have agreed to make the article open-access from February 18 through February 25, 2016 using this link: http://www.neurology.org/content/84/19/1948.short?sid=82de0570-ac50–41e6–998b–6e72904f7bd8

We’re also extremely pleased that author Dr. Maria A. Nagel has agreed to join the #RheumJC discussions to answer any questions you may have regarding the article.

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

OBSErve study: Belimumab in clinical practice

funny-cat-pic-rheumjc

Happy New Year 2016!

To kick off the year, we are very excited to announce the next #RheumJC on Thursday January 28, 2016. The article chosen for this first 2016 RheumJC is “Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA” by C. Collins, et al. It is published online by Lupus and is in open access: [CLICK HERE for open access article].

The first author of the article is our very own Christopher Collins known on twitter as @rheumpearls [CLICK HERE for profile]. He will be available during our usual two one-hour sessions at 9pm GMT (4pm EST) and 3am GMT (10pm EST) to answer all our questions.

This year’s RheumJC will be held every last Thursday of the month. We are also introducing some post session questions to consolidate the participants’ understanding on the subject. We encourage your participation and comments regarding these questions.

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.

  2. Be polite and courteous.

  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

Favorite Abstracts from the 2015 ACR Annual Meeting

ACR-poster-group

The next session of #RheumJC will be Thursday, December 10. We’ll be discussing three of your favorite abstracts from the 2015 ACR Annual Meeting based on your votes from our recent Twitter poll.

We will again run two one-hour “live chats” so as many people as possible can participate:

  • Session 1: 9pm GMT (4pm ET)
  • Session 2: 3am GMT (10pm ET)

ABSTRACT NUMBER: 505
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry

ABSTRACT NUMBER: 1075
The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)

ABSTRACT NUMBER: 3223
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

Also, if you’re interested in helping with #RheumJC over the next year, check our our post Expanding the #RheumJC Team.

Expanding the #RheumJC Team

shutterstock_194494349-600x500

Thanks!

We want to thank everyone for their amazing support of the #RheumJC project over the past year. At #ACR14, our Rheumatology Journal Club on Twitter began as a few a simple tweets that built momentum over the coming months, with the first journal club held in January.

Behind the Scenes

Above all, we’re a group that is interested in applying the power of Twitter to rheumatology education through Twitter.

We’re also full time clinical rheumatologists, so time is the limiting factor in us hosting more journal clubs.

For each journal club, we:

  • Pick an article (and if needed, contact the journal to ask for an open access link).
  • Try to contact authors of the article and invite them to participate, if possible.
  • Write an introductory blog post with dates/times and a short summary.
  • Send a copy of the blog post to our mailing list and schedule a shorter reminder the day of the journal club.
  • Have someone moderate each journal club session – which either requires some pre-typed tweets, or extremely fast typing skills.
  • Write a follow up blog post.
  • Write a short summary of the session to be included on the PubMed Commons portion of each discussed article.

Our efforts are coordinated using a popular team communications platform called Slack.

A Call for Help

Each journal club session optimally has 3–4 people involved in coordinating the above tasks. We’re looking for volunteers interested in being involved in any number of sessions over the next year. We’ll take all the help we can get!

With a little help, we can make #RheumJC even better over the next year, with more frequent sessions.

If you’re interested, let us know by letting us know on Twitter at @RheumJC or email at rheumjc@gmail.com.

Thanks!
– The #RheumJC Team